IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis

NCT ID: NCT00488839

Last Updated: 2019-11-06

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 173 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-06-30
• Study Completion Date: 2008-05-31

Brief Summary

The purpose of this study is to determine the effects, both good and bad, of IPX056 on subjects and their spasticity. This study will also determine the relationship between the amount of IPX056 in blood and the effects on spasticity. Lastly, this study will determine how long IPX056 affects spasticity.

Detailed Description

The primary objective of this study is to demonstrate that IPX056 reduces spasticity, measured by Ashworth score, in subjects with multiple sclerosis (MS). This study will also (1) assess the correlation between pharmacokinetic (PK) and pharmacodynamic (PD) endpoints (Ashworth score), and (2) quantify the duration of pharmacodynamic effects for IPX056 as well as marketed baclofen tablet in subjects with Multiple Sclerosis (MS) after a single dose. Additionally, the efficacy parameters, including Multiple Sclerosis Impact Scale (MSIS)-29, spasm frequency and nighttime awakening score, spasticity control, morning stiffness, and Global Assessment of Efficacy and Tolerability, will be assessed during open-label extension period. The safety of IPX056 will be monitored throughout the study.

This study consists of 2 parts: Part I (Screening Visit & Visit 1) of the study is a single-dose, double-blind, randomized, placebo- and active comparator-controlled, parallel group design containing a single 12 hour PK/PD evaluation period. Part II is an optional, approximately 9-week open-label extension study and will start during Visit 1, immediately after Visit 1 PK/PD procedures are completed.

Conditions

Multiple Sclerosis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

IPX056 20 mg - OLE

A single dose of IPX056 20 mg, Placebo IPX056 40 mg and Placebo Baclofen Tablet (Part 1), 9 week Open label extension of IPX056 (flexible dose design, IPX056 10 mg, IPX056 20 mg, IPX056 30 mg, IPX056 35 mg, or IPX056 40 mg)

Group Type: OTHER

IPX056 20 mg

Intervention Type: DRUG

IPX056 Extended Release capsule containing 20 mg baclofen

IPX056 40 mg

Intervention Type: DRUG

IPX056 Extended Release capsule containing 40 mg baclofen

Encapsulated Baclofen 20 mg

Intervention Type: DRUG

Baclofen 20mg tablet was encapsulated for blinding.

Placebo Baclofen Tablet

Intervention Type: DRUG

Placebo capsule encapsulated placebo Baclofen tablet

IPX056 10 mg

Intervention Type: DRUG

IPX056 Extended Release capsule containing 10 mg baclofen

IPX056 30 mg

Intervention Type: DRUG

IPX056 Extended Release capsule containing 30 mg baclofen

IPX056 35 mg

Intervention Type: DRUG

IPX056 Extended Release capsule containing 35 mg baclofen

Placebo IPX056 40 mg

Intervention Type: DRUG

Placebo capsule for IPX056 40 mg

IPX056 40 mg - OLE

A single dose of IPX056 40 mg, Placebo IPX056 20 mg and Placebo Baclofen Tablet (Part 1), 9 week Open label extension of IPX056 (flexible dose design, IPX056 10 mg, IPX056 20 mg, IPX056 30 mg, IPX056 35 mg, or IPX056 40 mg)

Group Type: OTHER

IPX056 20 mg

Intervention Type: DRUG

IPX056 Extended Release capsule containing 20 mg baclofen

IPX056 40 mg

Intervention Type: DRUG

IPX056 Extended Release capsule containing 40 mg baclofen

Encapsulated Baclofen 20 mg

Intervention Type: DRUG

Baclofen 20mg tablet was encapsulated for blinding.

Placebo Baclofen Tablet

Intervention Type: DRUG

Placebo capsule encapsulated placebo Baclofen tablet

IPX056 10 mg

Intervention Type: DRUG

IPX056 Extended Release capsule containing 10 mg baclofen

IPX056 30 mg

Intervention Type: DRUG

IPX056 Extended Release capsule containing 30 mg baclofen

IPX056 35 mg

Intervention Type: DRUG

IPX056 Extended Release capsule containing 35 mg baclofen

Placebo IPX056 20 mg

Intervention Type: DRUG

Placebo capsule for IPX056 20 mg

Baclofen 20 mg - OLE

A single dose of Encapsulated Baclofen 20 mg, Placebo IPX056 20 mg and Placebo IPX056 40 mg (Part 1), 9 week Open label extension of IPX056 (flexible dose design, IPX056 10 mg, IPX056 20 mg, IPX056 30 mg, IPX056 35 mg, or IPX056 40 mg)

Group Type: OTHER

IPX056 20 mg

Intervention Type: DRUG

IPX056 Extended Release capsule containing 20 mg baclofen

IPX056 40 mg

Intervention Type: DRUG

IPX056 Extended Release capsule containing 40 mg baclofen

Encapsulated Baclofen 20 mg

Intervention Type: DRUG

Baclofen 20mg tablet was encapsulated for blinding.

IPX056 10 mg

Intervention Type: DRUG

IPX056 Extended Release capsule containing 10 mg baclofen

IPX056 30 mg

Intervention Type: DRUG

IPX056 Extended Release capsule containing 30 mg baclofen

IPX056 35 mg

Intervention Type: DRUG

IPX056 Extended Release capsule containing 35 mg baclofen

Placebo IPX056 20 mg

Intervention Type: DRUG

Placebo capsule for IPX056 20 mg

Placebo IPX056 40 mg

Intervention Type: DRUG

Placebo capsule for IPX056 40 mg

Placebo - OLE

A single dose of Placebo Baclofen Tablet, Placebo IPX056 20 mg and Placebo IPX056 40 mg (Part 1), 9 week Open label extension of IPX056 (flexible dose design,IPX056 10 mg, IPX056 20 mg, IPX056 30 mg, IPX056 35 mg, or IPX056 40 mg)

Group Type: OTHER

IPX056 20 mg

Intervention Type: DRUG

IPX056 Extended Release capsule containing 20 mg baclofen

IPX056 40 mg

Intervention Type: DRUG

IPX056 Extended Release capsule containing 40 mg baclofen

Encapsulated Baclofen 20 mg

Intervention Type: DRUG

Baclofen 20mg tablet was encapsulated for blinding.

Placebo Baclofen Tablet

Intervention Type: DRUG

Placebo capsule encapsulated placebo Baclofen tablet

IPX056 10 mg

Intervention Type: DRUG

IPX056 Extended Release capsule containing 10 mg baclofen

IPX056 30 mg

Intervention Type: DRUG

IPX056 Extended Release capsule containing 30 mg baclofen

IPX056 35 mg

Intervention Type: DRUG

IPX056 Extended Release capsule containing 35 mg baclofen

Placebo IPX056 20 mg

Intervention Type: DRUG

Placebo capsule for IPX056 20 mg

Placebo IPX056 40 mg

Intervention Type: DRUG

Placebo capsule for IPX056 40 mg

Interventions

IPX056 20 mg

IPX056 Extended Release capsule containing 20 mg baclofen

Intervention Type: DRUG

IPX056 40 mg

IPX056 Extended Release capsule containing 40 mg baclofen

Intervention Type: DRUG

Encapsulated Baclofen 20 mg

Baclofen 20mg tablet was encapsulated for blinding.

Intervention Type: DRUG

Placebo Baclofen Tablet

Placebo capsule encapsulated placebo Baclofen tablet

Intervention Type: DRUG

IPX056 10 mg

IPX056 Extended Release capsule containing 10 mg baclofen

Intervention Type: DRUG

IPX056 30 mg

IPX056 Extended Release capsule containing 30 mg baclofen

Intervention Type: DRUG

IPX056 35 mg

IPX056 Extended Release capsule containing 35 mg baclofen

Intervention Type: DRUG

Placebo IPX056 20 mg

Placebo capsule for IPX056 20 mg

Intervention Type: DRUG

Placebo IPX056 40 mg

Placebo capsule for IPX056 40 mg

Intervention Type: DRUG

Other Intervention Names

Baclofen ER 20 mg; Baclofen ER 40 mg; Active comparator; Baclofen ER 10 mg; Baclofen ER 30 mg; Baclofen ER 35 mg

Eligibility Criteria

Inclusion Criteria

• Male or female at least 18 years old. If female and of childbearing potential, continuing to practice and willing to continue throughout the study with appropriate contraceptives (defined as oral, injected, or implanted contraceptives, or barrier contraception). The subject must agree to take every precaution to ensure that pregnancy will not occur during the study. Female subjects of childbearing potential must have a negative urine pregnancy test immediately prior to study entry.
• Able to understand and willing to voluntarily sign an informed consent form (ICF) and an Authorization to Use and Disclose Protected Health Information form (as required by the Health Insurance Portability and Accountability Act {HIPAA} legislation, if appropriate for the region) prior to the performance of any study-specific procedures.
• Has a negative urine drug screen at screening visit.
• Has Definite multiple sclerosis by Poser or McDonald Criteria.
• Expanded Disability Status Scale (EDSS) rating between 3.0-8.0
• Has a normal ECG and a blood pressure <160/95 mmHg (systolic)/diastolic) at screening, measured in the sitting position after approximately 5 minutes of quiet rest.
• If the subject has a history of or presence of clinically significant peptic ulcers, liver disease, diabetes mellitus, hypertension or heart disease, the subject must be on a stable treatment regimen for a minimum of 3 months prior to Screening Visit
• Wiling to wash out current medication with anti-spasticity activities, including but not limited to baclofen, benzodiazepines, clonazepam, clonidine, dantrolene, diazepam, gabapentin, and tizanidine.
• Ashworth score of 2 or more for at least one of the three lower extremity muscle groups (hip adductor, knee flexor, knee extensor) in the most affected limb and a total minimum score of 6 for four muscle groups (the above three plus plantar flexor) on both limbs (maximum total score is 32) during screening visit and at pre-dose during PK/PD Visit 1.
• Able and willing to comply with the protocol, including availability for all scheduled clinic visits

Exclusion Criteria

• If female, the subject is:

1. pregnant; or planning to become pregnant; or

2. breastfeeding; or

3. a woman of child-bearing potential (defined as post menarche and biologically capable of becoming pregnant [i.e., not surgically sterile]) who is engaged in active heterosexual relations and is not using a barrier or hormonal form of birth control (i.e. oral, injected, or implanted contraceptives).

• History of allergic or severe intolerance to baclofen.
• Did not respond to previous baclofen treatment in any formulation.
• Treated with intrathecal baclofen within the previous 6 months prior to the Screening Visit.
• Has experienced an exacerbation of MS within 6 months prior to the Screening Visit.
• Symptomatic urinary tract infection (UTI) within 4 weeks prior to the Screening Visit and more than two (2) UTI incidents within the last 6 months.
• Serum creatinine level ≥ 2 x ULN (upper limit of normal reference range) at the Screening Visit or requires dialysis.
• Liver enzyme values ≥ 2 x ULN (upper limit of normal reference range) at the Screening Visit.
• Uncontrolled peptic ulcers, liver disease, diabetes mellitus, bladder sphincter hypertonia, hypertension or heart disease.
• History of seizure or epilepsy, or is currently taking an anti-convulsant for treatment or control of seizure.
• Concomitant neurologic conditions causing spasticity (e.g. stroke, cerebral palsy, traumatic brain injury) or rigidity (e.g. Parkinson's disease).
• Any medical condition, including psychiatric disease, which would interfere with the interpretation of the study results, the conduct of the study, or the safety of the subject.
• Currently taking antipsychotics, CNS depressants or CNS depression producing medications (including alcohol, sedating antihistamines, barbiturates, narcotics, and phenothiazines), monoamine oxidase inhibitors (MAOI, including furazolidone, procarbazine, selegiline, and tranylcypromine), and tricyclics.
• Unable or unwilling to wash out current anti-spasticity medications, including but not limited to baclofen, benzodiazepines, clonazepam, clonidine, dantrolene, diazepam, gabapentin, and/or tizanidine for Day 1, Visit 1, procedures. However, these medications will be allowed during open label study.
• Unable or unwilling to participate 12-hour PK/PD procedures during Visit 1.
• Treated with Botulinum Toxin Type A or B within the previous 6 months, or Phenol or therapeutic alcohol nerve block within 12 months prior to the Screening Visit.
• History of alcohol abuse or use of recreational drugs within 12 months prior to the Screening Visit.
• Has received an investigational drug or device within 30 days prior to the Screening Visit.
• Has clinically significant limitation of passive range of motion around any of the joints being assessed in this study.
• Has had major surgery within 3 months prior to Screening visit that may affect spasticity assessments such as abdominal surgery, back surgery, lower leg and knee surgeries.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Impax Laboratories, LLC

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Impax Study Director

Role: STUDY_DIRECTOR

Impax Laboratories, LLC

Locations

Northwest NeuroSpecialists

Tucson, Arizona, United States

OrthoArkansas, P. A.

Little Rock, Arkansas, United States

OrthoArkansas, P.A.

Little Rock, Arkansas, United States

Patricia Fodor

Colorado Springs, Colorado, United States

Sunrise Clinical Research

Hollywood, Florida, United States

Meridien Research

Tampa, Florida, United States

MS Center of Atlanta

Atlanta, Georgia, United States

OSF Saint Francis Medical Center

Peoria, Illinois, United States

Elkhardt Clinic

Elkhart, Indiana, United States

MidAmerica Neuroscience Institute

Lenexa, Kansas, United States

Springfield Neurology

Springfield, Massachusetts, United States

General Clinical Research Center 7A

Ann Arbor, Michigan, United States

Medex Healthcare Research, Inc.

Saint Louis, Michigan, United States

Northern Michigan Neurology

Traverse City, Michigan, United States

Winthrop University Hospital

Mineola, New York, United States

Crozer Chester Medical Center

Upland, Pennsylvania, United States

Bhupesh Dihenia

Lubbock, Texas, United States

Integra Clinical Research

San Antonio, Texas, United States

Neurological Research Center

Bennington, Vermont, United States

Virginia Commonwealth University Medical Center

Richmond, Virginia, United States

Montreal Neurological Institute and Hospital

Montreal, Quebec, Canada

Foothills Medical Centre, MS Clinic, SSB

Calgary, , Canada

West-Tallinn Central Hospital

Tallinn, , Estonia

Vecmilgravis Hospital, Latvian Maritime Medicine Center

Riga, , Latvia

Chernihiv Regional Hospital Department of Neurology

Chernihiv, , Ukraine

Neurology and Neurosurgery Dpt., Postgraduation training faculty, Dnipropetrovsk State medical Academy

Dnipropetrovsk, , Ukraine

Institue of Neruology, Psychiatry and Narcology of AMS of Ukraine

Kharkiv, , Ukraine

Department of nervous system demyelization diseases of City Clinical Hospital

Kyiv, , Ukraine

Odessa Regional Clinical Hospital

Odesa, , Ukraine

Neurology department of Ukraine medical stomatological akademy

Poltava, , Ukraine

Vinnytsya Regional Psychoneurological Hospital

Vinnytsia, , Ukraine

Countries

United States; Canada; Estonia; Latvia; Ukraine

Other Identifiers

2007-000236-16

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

IPX056-B06-03

Identifier Type: -

Identifier Source: org_study_id